Home › Trials › NCT06867705

Remote symptom monitoring with Resilience PRO versus usual care for adults with cancer on systemic treatment

Digital Monitoring With Patient-Reported Outcomes in Cancer Care: A Randomized Controlled Trial RC - 102 (Resilience Care - 102)

Phase 3 Interventional Resilience · NCT06867705

This trial tests whether the Resilience PRO smartphone app for remote symptom monitoring helps adults with cancer on systemic therapy have better quality of life than usual care.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment1458 (estimated)
Ages18 Years and up
SexAll
SponsorResilience Industry-sponsored
Drugs / interventionsCAR-T
Locations36 sites (Aix-en-Provence and 35 other locations)
Trial IDNCT06867705 on ClinicalTrials.gov

What this trial studies

Adults with cancer who are receiving systemic anticancer therapy are randomized to use Resilience PRO plus usual care or to receive usual care alone. Resilience PRO is a CE-marked digital medical device that collects patient-reported symptoms via a smartphone app, performs intelligent analysis, and sends alerts to the care team for clinically important symptoms. The study tracks quality of life outcomes while also allowing clinicians to incorporate alerts into timely care adjustments. Participants must have smartphone access and be treated at participating centers in France.

Who should consider this trial

Good fit: Ideal candidates are adults (18+) with any-stage cancer receiving systemic anticancer therapy who can use a smartphone, give informed consent, and speak the trial language.

Not a fit: Patients unlikely to benefit include those with life expectancy under six months, those already enrolled in other remote-monitoring programs, patients undergoing HSCT or CAR-T, pregnant or breastfeeding individuals, or those with significant cognitive impairment.

Why it matters

Potential benefit: If successful, the app could improve patients' quality of life by enabling earlier symptom recognition and timelier care adjustments.

How similar studies have performed: Previous randomized studies of remote symptom monitoring in cancer have shown improved quality of life and reduced emergency visits, so the general approach has supporting evidence, though device-specific data for Resilience PRO are limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age: Adults ≥ 18 years.
* Informed Consent: Patient giving signed informed consent to participate in the RC - 102 clinical study.
* Diagnosis: Patients with cancer at any stage.
* Systemic Treatment
* Remote Monitoring Eligibility: Access to a smartphone
* Language: Ability to understand and communicate in the language(s) in which the trial is conducted.

Exclusion Criteria:

* Age: Patients under 18 years of age.
* Life Expectancy: Patients with a life expectancy of less than 6 months as estimated by the treating physician.
* Concurrent remote monitoring
* HSCT or CAR-T Therapy
* Cognitive Impairment
* Pregnancy or breastfeeding
* Subject under administrative or judicial control

Where this trial is running

Aix-en-Provence and 35 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions CancerRemote Patient MonitoringRemote Symptom MonitoringDigital medicineResilience PROResiliencePROPatient-reported Outcomes
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.